Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib Immune Effects in BRAF-Mutated Melanoma
NCT01942993Phase 2Terminated
- Start
- Sep 2013
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib in melanoma. Started Sep 2013; status: terminated.
02
Drugs
vemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01942993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01942993.